HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 0091270008318007v1 48/6/726    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Iwamoto, M. Articles by Wagner, J. A. Search for Related Content PubMed PubMed Citation Articles by Iwamoto, M. Articles by Wagner, J. A. Social Bookmarking                   What's this?

Raltegravir Thorough QT/QTc Study: A Single Supratherapeutic Dose of Raltegravir Does Not Prolong the QTcF Interval

From Merck & Co, Inc, Whitehouse Station, New Jersey (Dr Iwamoto, Dr Kost, G. C. Mistry, Dr Wenning, S. A. Breidinger, Dr Stone, Dr Gottesdiener, Dr Bloomfield, Dr Wagner) and Orlando Clinical Research Center, Orlando, Florida (Dr Marbury).

Raltegravir is a novel HIV-1 integrase inhibitor with potent in vitro activity (IC₉₅ = 31 nM in 50% human serum). A double-blind, randomized, placebo-controlled, double-dummy, 3-period, single-dose crossover study was conducted; subjects received single oral doses of 1600 mg raltegravir, 400 mg moxifloxacin, and placebo. The upper limit of the 2-sided 90% confidence interval for the QTcF interval placebo-adjusted mean change from baseline of raltegravir was less than 10 ms at every time point. For the raltegravir and placebo groups, there were no QTcF values >450 ms or change from baseline values >30 ms. A mean C_max of 20 µM raltegravir was attained, 4-fold higher than the C_max at the clinical dose. Moxifloxacin demonstrated an increase in QTcF at the 2-, 3-, and 4-hour time points. Administration of a single supratherapeutic dose of raltegravir does not prolong the QTcF interval. A single supratherapeutic dose design may be appropriate for crossover thorough QTc studies.

Key Words: Raltegravir • HIV-1 integrase inhibitor • QTc interval • thorough QT • ECG

Address for reprints: Marian Iwamoto, MD, PhD, Merck & Co, Inc, RY34-A500, PO Box 2000, Rahway, NJ 07065-0900; e-mail: marian_iwamoto{at}merck.com.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Malik, K. Hnatkova, A. Schmidt, and P. Smetana Electrocardiographic QTc Changes Due to Moxifloxacin Infusion J. Clin. Pharmacol., June 1, 2009; 49(6): 674 - 683. [Abstract] [Full Text] [PDF]